Retatrutide: The Triple-Agonist With the Biggest Weight Signal

The short version

Retatrutide — also known by its development code LY3437943 — is a synthetic 39-amino-acid peptide built to activate three metabolic receptors at once: the GLP-1 receptor (suppresses appetite), the GIP receptor (amplifies insulin secretion and fat handling), and the glucagon receptor (increases energy expenditure and fat mobilization). No other approved or near-approval compound hits all three simultaneously.

The Phase 2 clinical program has produced the largest published weight-loss signal for any pharmaceutical: a mean -24.2% body-weight change at 48 weeks at the highest dose versus -2.1% for placebo ^[4]. In a parallel Phase 2 substudy in participants with liver disease, 86% reached normal liver fat at 24 weeks ^[3]. In a type 2 diabetes trial, HbA1c dropped by -2.02% at 24 weeks alongside -16.94% body weight by 36 weeks ^[5].

The direct answer to the regulatory question: retatrutide is not approved by the FDA or any other regulator as of mid-2026. It is in Phase 3 trials (the TRIUMPH program, run by Eli Lilly). What is sold through research channels is unverified material that cannot be confirmed as authentic retatrutide ^[4]. This page describes the clinical research record; it gives no dose and no advice.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid acylation at one end that binds albumin in the bloodstream and extends the peptide's working life — yielding an approximately 6-day half-life ^[6] that supports once-weekly injection in the trial protocol. Its molecular formula (free acid) is C221H342N46O68.

The compound is classified as a GIP/GLP-1/glucagon receptor triagonist. That label matters because it distinguishes retatrutide from dual agonists (GIP + GLP-1 only) and from single-mechanism GLP-1 receptor agonists: the added glucagon-receptor arm is what drives the energy-expenditure component. Cryo-EM structural work confirms that retatrutide engages all three receptors — approximately 8.9x more potently at GIPR than native GIP, but at lower relative potency at GCGR and GLP-1R compared to their respective native hormones ^[2]. It has no approved brand name, no approved indication, and no prescription availability.

How it works

Retatrutide is a single molecule acting on three receptors at once. The GLP-1 arm suppresses appetite and slows gastric emptying by activating GLP-1 receptors in the gut, brain, and pancreas — the same mechanism shared with other GLP-1-class compounds. The GIP arm augments glucose-dependent insulin secretion from the pancreas and modulates fat-cell handling of lipids; GIPR agonism is thought to amplify the appetite suppression of GLP-1R and improve tolerability. The glucagon arm is the differentiator: GCGR activation increases hepatic glucose output, drives lipolysis (fat breakdown for energy), and raises thermogenesis — the body burns more energy even at rest ^[1][2].

The combination is additive: post-hoc metabolomic and lipidomic analysis of two Phase 2 trials found that higher retatrutide doses reduced triglycerides and insulin-resistance biomarkers (branched-chain amino acids, 2-hydroxybutyrate, urate), with changes in fatty acid oxidation mediating 23.2% of the weight-reduction response in non-T2D participants ^[7]. In plain terms: it suppresses how much you want to eat, improves how the body handles glucose, and pushes the body to burn more energy simultaneously.

What the research shows

Phase 2 obesity trial — the headline number. In 338 adults with obesity, once-weekly retatrutide at the highest dose produced a mean body-weight change of -24.2% at 48 weeks versus -2.1% for placebo — with GI adverse events dose-related and mostly mild-to-moderate, and a dose-dependent heart-rate increase peaking at 24 weeks ^[4]. That weight-loss magnitude exceeds published 48-week results for dual agonists and is the largest published figure for any pharmacological agent in a controlled trial.

MASLD substudy. In 98 participants with obesity and metabolic dysfunction-associated steatotic liver disease, retatrutide 12 mg reduced liver fat by a relative -82.4% at 24 weeks; 86% of participants at that dose reached normal (<5%) liver fat. Reductions were sustained at 48 weeks (-86.0% at 12 mg) ^[3]. This is among the strongest liver-fat reduction signals published for any compound.

Type 2 diabetes trial. In 281 adults with type 2 diabetes, retatrutide 12 mg lowered HbA1c by -2.02% at 24 weeks and reduced body weight by -16.94% at 36 weeks versus -0.01% and -3.00% for placebo. No severe hypoglycemia and no deaths occurred ^[5].

First-in-human Phase 1b. The initial ascending-dose trial in 72 adults with type 2 diabetes established the approximately 6-day half-life supporting weekly dosing. The highest-dose group lost -8.96 kg (placebo-adjusted, 90% CI -11.16 to -6.75) over just 12 weeks ^[6].

Receptor structure. Cryo-EM studies resolved the triple-agonist binding to all three receptor complexes at 2.68/3.26/2.84 angstrom resolution, confirming genuine simultaneous engagement ^[2].

Metabolomics. Post-hoc analysis of Phase 2 data from obesity and T2D cohorts showed dose-dependent reductions in triglycerides and insulin-resistance biomarkers, with fatty acid oxidation changes mediating a meaningful fraction of the weight effect ^[7].

Reported effects, cautions & safety

Research-community reports (anecdotal, not clinical evidence). People using retatrutide in research contexts frequently report near-total silencing of intrusive food thoughts — a phenomenon community members call "food noise going quiet." Rapid and pronounced weight reduction is described as qualitatively faster than experiences with other GLP-1-class compounds, which broadly aligns with the Phase 2 trial magnitudes. A commonly noted side experience is a mild warmth or thermogenic sensation, widely attributed to glucagon-receptor activity. On the adverse side, nausea peaking 4-8 hours post-injection and most pronounced during initial weeks and dose escalation is the most common complaint; sulfur burps, constipation, fatigue in the first weeks, and elevated resting heart rate (some community members note 5-15 bpm above baseline on wearables) are also frequently reported. Sleep disturbances and lean-mass concern with rapid weight loss are occasionally noted. All of these are unverified self-reports from research-use communities with no confirmed doses or clinical oversight.

Safety cautions from the clinical literature:

• Unapproved and unverified supply. Retatrutide is investigational and has not been approved by any regulator. Material obtained outside a clinical trial cannot be confirmed to be authentic retatrutide of known purity, identity, or sterility. The FDA issued over 50 warning letters to retatrutide vendors in 2025 citing Federal FD&C Act violations.
• GI adverse events as the leading discontinuation cause. Nausea affected up to 45% of participants at the highest Phase 2 dose and drove an 18% discontinuation rate. In unmonitored settings there is no dose-escalation oversight, increasing the risk of dehydration and electrolyte imbalance ^[4].
• Dose-dependent heart-rate increase. Mean increases of approximately 5-7 bpm were documented in Phase 2, peaking around 24 weeks. Individuals with pre-existing arrhythmias or cardiovascular disease face unmonitored risk ^[1][4].
• Hypoglycemia risk with insulin or sulfonylureas. Combined glucose-lowering effects can produce dangerous blood-glucose drops in people already on insulin or sulfonylurea medications ^[5][6].
• Lean-mass reduction. Body-composition data confirm retatrutide reduces lean mass in addition to fat; resistance training and adequate protein intake are relevant protective co-practices ^[1].
• Long-term safety unknown. The TRIUMPH Phase 3 trials and dedicated cardiovascular and kidney outcome trials are ongoing as of mid-2026; no long-term outcomes data exist ^[1][4].

Where it fits in metabolic research

Among the three peptides on this desk, retatrutide carries the strongest and most recent human evidence — two completed Phase 2 trials in humans with direct efficacy and safety measurements, and an ongoing Phase 3 program. It sits at the far end of the clinical-evidence spectrum compared to MOTS-c, which has no human intervention data at all, and it differs from tesamorelin in both mechanism (receptor-level appetite and energy signaling vs. GH-axis stimulation) and regulatory status (investigational vs. narrowly approved). Its defining limitation is regulatory: it is not yet approved, and material obtained outside a supervised trial is unregulated and unverified. See the comparison page for how it lines up.